Sequencing of agents for metastatic renal cell carcinoma: Can we customize therapy?

European Urology

Volumn 61, Issue 2, 2012, Pages 307-316

  Sonpavde, Guru ^a,b   Choueiri, Toni K ^c   Escudier, Bernard ^d   Ficarra, Vincenzo ^e   Hutson, Thomas E ^f   Mulders, Peter F ^g   Patard, Jean Jacques ^h   Rini, Brian I ⁱ   Staehler, Michael ^j   Sternberg, Cora N ^k   Stief, Christian G ^j  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY OF PADOVA   (Italy)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h BICÊTRE HOSPITAL   (France)

ⁱ TAUSSIG CANCER INSTITUTE   (United States)

^j UNIVERSITY OF MUNICH   (Germany)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

more..

Author keywords

Axitinib; Everolimus; Renal cell carcinoma; Second line therapy; Tyrosine kinase inhibitor

Indexed keywords

AXITINIB; B RAF KINASE; BEVACIZUMAB; CD135 ANTIGEN; DOVITINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ARTERY THROMBOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CYTOPENIA; DIARRHEA; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DYSPHONIA; FATIGUE; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IC 50; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LIVER TOXICITY; METABOLISM; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; PATIENT SELECTION; PEER REVIEW; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 83955162846     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.10.032     Document Type: Review

References (59)

1. D.F. McDermott, M.M. Regan, and J.I. Clark Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141
2. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
3. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
4. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
5. B. Escudier, J. Bellmunt, and S. Negrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
6. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
7. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
8. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
9. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
10. M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
11. D. Huang, Y. Ding, and M. Zhou Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res 70 2010 1063 1071
12. J. Finke, J. Ko, B. Rini, P. Rayman, J. Ireland, and P. Cohen MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy Int Immunopharmacol 11 2011 856 861
13. J.D. Gordan, P. Lal, and V.R. Dondeti HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma Cancer Cell 14 2008 435 446
14. A.R. Brannon, A. Reddy, and M. Seiler Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns Genes Cancer 1 2010 152 163
15. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
16. R.J. Motzer, B.I. Rini, and R.M. Bukowski Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2006 2516 2524
17. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
18. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
19. D. Nosov, P. Bhargava, and W.B. Esteves Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma J Clin Oncol 29 Suppl 2001 [abstract 4550]
20. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
21. M.B. Atkins, M. Hidalgo, and W.M. Stadler Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
22. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
23. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
24. T.E. Hutson, S. Bracarda, and B. Escudier Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy J Clin Oncol 29 Suppl 7 2011 [abstract 312]
25. M.J. Mackenzie, B.I. Rini, and P. Elson Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2010 145 148
26. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
27. J.P. Dutcher, G. Wilding, and G.R. Hudes Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone J Clin Oncol 26 Suppl 2008 [abstract 5127]
28. B.I. Rini, B. Escudier, and P. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial J Clin Oncol 29 Suppl 2011 [abstract 4503]
29. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34 discussion 34
30. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
31. J.A. Reeves, D. Spigel, D.B. Daniel, E.K. Friedman, H.A. Burris, and J.D. Hainsworth Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: a Sarah Cannon Research Institute phase II trial J Clin Oncol 29 Suppl 2011 [abstract 4659]
32. J.A. Garcia, T.E. Hutson, and P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
33. B.I. Rini, M.D. Michaelson, and J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
34. S. Bracarda, J. Bellmunt, and B. Melichar Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial BJU Int 107 2011 214 219
35. D. Miles, N. Harbeck, and B. Escudier Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials J Clin Oncol 29 2011 83 88
36. I.N. Zama, T.E. Hutson, and P. Elson Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 2010 5400 5406
37. H.J. Hammers, H.M. Verheul, and B. Salumbides Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol Cancer Ther 9 2010 1525 1535
38. M.M. Vickers, T.K. Choueiri, and M. Rogers Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2010 430 434
39. D.Y. Heng, M. MacKenzie, and U.N. Vaishampayan Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy J Clin Oncol 29 Suppl 7 2011 [abstract 305]
40. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
41. D.C. Cho, I. Puzanov, and M.M. Regan Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma J Immunother 32 2009 181 185
42. G. Di Lorenzo, C. Buonerba, and P. Federico Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 2010 906 911
43. D.Y. Heng, W. Xie, and G.A. Bjarnason A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study J Clin Oncol 28 Suppl 2010 15s [abstract 4523]
44. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
45. A. Grothey, and D. Sargent Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line J Clin Oncol 23 2005 9441 9442
46. M.Y. Al-Marrawi, B. Rini, and L.C. Harshman The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients J Clin Oncol 29 Suppl 2011 [abstract 4555]
47. T.K. Choueiri, F.A. Schutz, Y. Je, J.E. Rosenberg, and J. Bellmunt Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
48. B.I. Rini, D.P. Cohen, and D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
49. C. Pena, C. Lathia, M. Shan, B. Escudier, and R.M. Bukowski Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Clin Cancer Res 16 2010 4853 4863
50. Z. Jiang, P.G. Chu, and B.A. Woda Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study Lancet Oncol 7 2006 556 564
51. C.F. Xu, N.X. Bing, and H.A. Ball Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes J Clin Oncol 29 2011 2557 2564
52. T.K. Choueiri, S.A. Vaziri, and E. Jaeger Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 2008 860 865 discussion 865-6
53. D. Cho, S. Signoretti, and S. Dabora Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma Clin Genitourin Cancer 5 2007 379 385
54. K.M. Krajewski, M. Guo, and A.D. Van den Abbeele Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma Eur Urol 59 2011 856 862
55. A.D. Smith, S.N. Shah, B.I. Rini, M.L. Lieber, and E.M. Remer Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy AJR Am J Roentgenol 194 2010 1470 1478
56. W.W. Ma, H. Jacene, and D. Song [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy J Clin Oncol 27 2009 2697 2704
57. I. Katani, N.E. Avril, and J. Bomanji Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer Clin Cancer Res 17 2011 6021 6028
58. O.M. Hahn, C. Yang, and M. Medved Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma J Clin Oncol 26 2008 4572 4578
59. N. Lassau, S. Koscielny, and L. Albiges Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography Clin Cancer Res 16 2010 1216 1225